17.31

1.59% -0.28

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $17.31, with a volume of 52,651. It is down -1.59% in the last 24 hours and up +31.14% over the past month. Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Previous Close:

$17.59

Open:

$17.75

24h Volume:

52,651

Relative Volume:

1.21

Market Cap:

$733.05M

Revenue:

Net Income/Loss:

$-75.28M

P/E Ratio:

-12.19

EPS:

-1.42

Net Cash Flow:

$-57.45M

1W Performance:

+2.00%

1M Performance:

+31.14%

6M Performance:

+35.23%

1Y Performance:

+76.63%

1-Day Range:

$17.30

$17.88

1-Week Range:

$16.83

$18.00

52-Week Range:

$9.60

$18.00

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OCS's Discussions on Twitter

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

Oculis Holding Ag Stock (OCS) Latest News

Nov 04, 2024

Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39% - Yahoo Finance

Oct 30, 2024

Oct 28, 2024

Oculis (NASDAQ:OCS) Reaches New 1-Year HighStill a Buy? - MarketBeat

Oct 28, 2024

Oct 27, 2024

Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 133.7% - MarketBeat

Oct 27, 2024

Oct 26, 2024

Trading (OCS) With Integrated Risk Controls - Stock Traders Daily

Oct 26, 2024

Oct 25, 2024

Oculis (NASDAQ:OCS) Shares Gap DownHere's Why - MarketBeat

Oct 25, 2024

Oct 23, 2024

Oculis (NASDAQ:OCS) Shares Gap UpHere's Why - MarketBeat

Oct 23, 2024

HC Wainwright Reaffirms "Buy" Rating for Oculis (NASDAQ:OCS) - MarketBeat

Oct 23, 2024

Financial Comparison: Oculis (NASDAQ:OCS) and Terns Pharmaceuticals (NASDAQ:TERN) - Defense World

Oct 23, 2024

Oct 22, 2024

Oculis (NASDAQ:OCS) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 22, 2024

Oculis Holding AG's (NASDAQ:OCS) market cap touched US$586m last week, benefiting both individual investors who own 55% as well as institutions - Simply Wall St

Oct 22, 2024

Oct 21, 2024

Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials - TipRanks

Oct 21, 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - StockTitan

Oct 21, 2024

Oculis (NASDAQ:OCS) Trading Up 4.8%Here's What Happened - MarketBeat

Oct 21, 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 - GlobeNewswire

Oct 21, 2024

Oct 15, 2024

OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan

Oct 15, 2024

Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema - GlobeNewswire

Oct 15, 2024

Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - StockTitan

Oct 15, 2024

Oct 09, 2024

Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Oct 09, 2024

Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews

Oct 09, 2024

Oct 08, 2024

Oculis (NASDAQ:OCS) Hits New 52-Week High – Here’s What Happened - Defense World

Oct 08, 2024